Cleared Special

CONTOUR® NEXT ONE Blood Glucose Monitoring System (K210687) - FDA 510(k) Clearance

Class II Chemistry device cleared through the Special 510(k) pathway - typically does not require clinical trials.

K210687 · Ascensia Diabetes Care · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2021
Decision
156d
Days
Class 2
Risk

K210687 is an FDA 510(k) clearance for the CONTOUR® NEXT ONE Blood Glucose Monitoring System. Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Ascensia Diabetes Care (Valhalla, US). The FDA issued a Cleared decision on August 11, 2021 after a review of 156 days - an extended review cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Standard predicate reliance. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Ascensia Diabetes Care devices

Submission Details

510(k) Number K210687 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 08, 2021
Decision Date August 11, 2021
Days to Decision 156 days
Submission Type Special
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
68d slower than avg
Panel avg: 88d · This submission: 156d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 165
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K210687.
CareSens N Feliz Blood Glucose Monitoring System, CareSens N Feliz BT Blood Glucose Monitoring System
K201394 · I-Sens, Inc. · Oct 2021
GlucoSure HT Plus Blood Glucose Monitoring System
K202885 · Apex BioTechnology Corp. · Sep 2021
EASYMAX Tag Self-Monitoring Blood Glucose System
K201258 · Eps Bio Technology Corp. · Sep 2021
Finetest Lite Blood Glucose Monitoring System
K203562 · Osang Healthcare Co. , Ltd. · Jul 2021
Finetest Lite Smart Blood Glucose Monitoring System
K201396 · Osang Healthcare Co. , Ltd. · Oct 2020
GoChek Blood Glucose Monitoring System, GoChek Connect Blood Glucose Monitoring System
K193340 · Microtech Medical, Inc. · Sep 2020